Brain Cancer

P1, N=56, Recruiting, Baylor College of Medicine | N=37 --> 56

P=N/A, N=26, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

P=N/A, N=27, Recruiting, Peking University Third Hospital

This limited contribution likely reflects the fact that synthetic PET is derived from MRI and cannot capture true tracer-driven metabolic or molecular information. These findings highlight the need to validate information complementarity before integrating synthesized modalities into clinical workflows.

P=N/A, N=20, Active, not recruiting, Columbia University | Recruiting --> Active, not recruiting

P1, N=28, Not yet recruiting, University of Alabama at Birmingham | Trial completion date: Aug 2027 --> Aug 2029 | Trial primary completion date: Aug 2027 --> Aug 2029

Germ cell tumors can present as extra-axial dura-based lesions and should be suspected in young patients with imaging showing lesions with cystic or hemorrhagic components. Pulmonary metastases are infrequent but may be present. For successful treatment, chemotherapy and radiation therapy should always be considered. https://thejns.org/doi/10.3171/CASE25855.

Despite multimodal treatments, including surgery, radiation therapy, and temozolomide (TMZ) chemotherapy, the median survival remains poor at approximately 15 months...Furthermore, we demonstrate that overexpression of BCL2 increased TMZ resistance in GICs and their tumorigenicity, while its knockdown deprived these malignant characters in GICRs. Taken together, these findings identify a novel signaling pathway, MAP17-NF-κB-BCL2, that controls TMZ resistance and tumorigenicity of GICs.

The TAM receptors' ligand GAS6 and the AXL/GAS6 ratio could help to monitor patients' prognosis in metastatic CRC settings including BM-CRC. Further research is needed to validate the TAM receptors' impact on prognosis in BM-CRC.

Clinical validation has confirmed that this dual-channel synergistic detection strategy can accurately identify the IDH1.R132H mutation in glioma patients with as little as 1 µL of sample, and deliver crucial clinical information such as tumor size and staging. This label-free, rapid, cost-effective, and highly sensitive biosensing platform offers a powerful tool for early cancer screening, molecular diagnostics, and longitudinal disease monitoring.

This is the first report in clinical samples showing that ipatasertib efficiently depletes FOXP3+ regulatory T cells and results in increased infiltration of effector CD8+ T cells in the tumor microenvironment. This was associated with preliminary efficacy in a subset of patients with treatment-refractory glioblastoma (GBM).

Emerging evidence also reveals that toxin-mediated cytotoxicity can enhance antitumor immune responses, supporting their integration with immunotherapy. These advances position targeted toxins as precision cytotoxic compounds whose success depends on coordinated molecular targeting, delivery optimization, and biologically stratified patient selection, establishing a translational pathway for future glioma therapy.